Revolution Medicines is a late‑stage clinical oncology company developing novel targeted therapies for patients with RAS‑addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins, including daraxonrasib, elironrasib, zoldonrasib, and RMC‑5127, all of which are currently in clinical development. The Opportunity The Executive Director, Head of Quality, Europe will lead and oversee all Quality functions across the European region, ensuring compliance with European regulatory requirements. This strategic and operational role spans GxP Quality (GMP, GDP, GCP as applicable) and serves as the key Quality representative for Europe, partnering with Regulatory Affairs, Manufacturing, Supply Chain, Clinical Operations, and external partners to maintain a robust, inspection‑ready quality system. Key Responsibilities Lead and develop the European Quality organization, aligning with global strategy and supporting the tra...